Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $131.4 million.

  • Catalyst Pharmaceuticals' Total Liabilities rose 1826.61% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.4 million, marking a year-over-year increase of 1826.61%. This contributed to the annual value of $123.8 million for FY2024, which is 5052.23% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Total Liabilities stood at $131.4 million, which was up 1826.61% from $115.9 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Total Liabilities high stood at $131.4 million for Q3 2025, and its period low was $18.6 million during Q1 2021.
  • For the 5-year period, Catalyst Pharmaceuticals' Total Liabilities averaged around $71.3 million, with its median value being $73.6 million (2023).
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Total Liabilities decreased by 12.06% in 2021 and then soared by 17500.28% in 2023.
  • Catalyst Pharmaceuticals' Total Liabilities (Quarter) stood at $31.0 million in 2021, then soared by 142.95% to $75.2 million in 2022, then rose by 9.34% to $82.2 million in 2023, then surged by 50.52% to $123.8 million in 2024, then grew by 6.12% to $131.4 million in 2025.
  • Its Total Liabilities stands at $131.4 million for Q3 2025, versus $115.9 million for Q2 2025 and $114.6 million for Q1 2025.